Cullinan Therapeutics, Inc. CGEM Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Cullinan Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cullinan Therapeutics, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cullinan Therapeutics, Inc.'s other commercial liabilities?
- Cullinan Therapeutics, Inc. (CGEM) reported other commercial liabilities of $31.92M in Q1 2026.
- How has Cullinan Therapeutics, Inc.'s other commercial liabilities changed year-over-year?
- Cullinan Therapeutics, Inc.'s other commercial liabilities increased by 41.2% year-over-year, from $22.6M to $31.92M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s other commercial liabilities?
- Over 5 years (2020 to 2025), Cullinan Therapeutics, Inc.'s other commercial liabilities has grown at a 50.7% compound annual growth rate (CAGR), from $4.64M to $36.12M.